Close Menu
Qiagen to Buy Digene for $1.6B; Merger Links US-Europe Molecular Dx Strategy
 
Qiagen announced plans over the weekend to purchase diagnostics firm Digene in a cash and stock deal valued at around $1.6 billion.
 
Under the terms of the agreement, Digene shareholders will receive either $61.25 in cash for each share of Digene stock they hold or 3.545 shares of Qiagen's stock.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Springer Nature announces €9,500 fee to make papers open-access in Nature and its family of journals.

Librarians have concluded that notebooks that belonged to Charles Darwin that were thought to have been lost were actually likely stolen, CNN reports.

An early SARS-CoV-2 alteration may have enabled it to spread more easily, according to the New York Times.

In PNAS this week: ultrarare variants contribute to aging-related hearing loss, telomeres of cells infected with herpesvirus, and more.

Dec
01
Sponsored by
Roche

Management of viral infections is critical to prevent severe morbidities and consequences in immune-suppressed transplant patients.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.

Dec
15
Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.